+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years +
All Genders
ID05569382

Comparing Effects of Bisoprolol and Verapamil in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Led by Morten Steen Kvistholm Jensen · Updated on 2025-03-20

100

Participants Needed

4

Research Sites

39 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the treatment effects of Bisoprolol, a beta 1 receptor-specific beta blocker, and Verapamil, a cardio-specific calcium channel blocker, in patients with non-obstructive hypertrophic cardiomyopathy HCM. HCM is characterized by thickening of the left ventricular wall and increased sarcomere contraction, which reduces the left ventricular cavity size. Symptoms include breathlessness, chest pain, palpitations, and fainting, with risks of arrhythmias and sudden cardiac deaths. Current treatments include beta blockers and calcium channel blockers, but evidence on their effectiveness is limited. This study is a multicenter, randomized, triple-blinded, placebo-controlled crossover trial involving three 35-day treatment periods. Participants receive Bisoprolol, Verapamil, and placebo in random order, each period including a week of dose increase, three weeks at target dose, and a week of dose reduction. A 45-day treatment pause separates each period. Dosages can reach up to 7.5 mg per day for Bisoprolol and 360 mg per day for Verapamil. A subgroup will also undergo cardiac magnetic resonance imaging. During the trial, patients will undergo cardiopulmonary exercise testing, echocardiography, seven-day Holter monitoring, biomarker assessments, and complete the Kansas City Cardiomyopathy Questionnaire. Researchers will assess maximal oxygen consumption, left ventricular volume, and incidence of non-sustained ventricular tachycardia among other heart function measures. The study includes safety monitoring and evaluates symptoms, heart function, and arrhythmia occurrence over the treatment periods, with outcomes measured mainly at day 21 of each treatment.

CONDITIONS

Brief Title

Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy

Research Team

M

Morten SK Jensen

L

Louise Bjerregaard

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here